drugset

Drugs / ACR-368

Follow last change Apr 2026 re-read 3 minutes ago

ACR-368

Developed for: endometrium adenocarcinoma · head and neck squamous cell carcinoma
Investigated by: Acrivon Therapeutics · GOG Foundation · H. Lee Moffitt Cancer Center and Research Institute

Trials 2

today NCT06597565 · Ph 2 NCT05548296 · Ph 2

202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT06597565	Sep 2024 → Aug 2028 expected	head and neck squamous cell carcinoma	H. Lee Moffitt Cancer Center and Research Institute	Recruiting	No outcome recorded
Phase 2	NCT05548296	Aug 2022 → May 2027 expected	endometrium adenocarcinoma	Acrivon Therapeutics	Recruiting	No outcome recorded

Press releases naming this drug 18 releases

Date	Issuer	Release
2026-04-17	Acrivon Therapeutics	Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities acrivon.com ↗
2026-03-17	Acrivon Therapeutics	Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors acrivon.com ↗
2026-02-23	Acrivon Therapeutics	Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress acrivon.com ↗
2026-01-08	Acrivon Therapeutics	Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 acrivon.com ↗
2026-01-06	Acrivon Therapeutics	Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast acrivon.com ↗
2025-12-17	Acrivon Therapeutics	Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast acrivon.com ↗
2025-03-19	Acrivon Therapeutics	Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates acrivon.com ↗
2025-02-05	Acrivon Therapeutics	Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer acrivon.com ↗
2024-09-14	Acrivon Therapeutics	Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis acrivon.com ↗
2024-09-09	Acrivon Therapeutics	Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316 acrivon.com ↗
2024-04-24	Acrivon Therapeutics	Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event acrivon.com ↗
2024-04-16	Acrivon Therapeutics	Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 acrivon.com ↗
2024-04-10	Acrivon Therapeutics	Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368 acrivon.com ↗
2023-11-28	Acrivon Therapeutics	Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer acrivon.com ↗
2023-10-16	Acrivon Therapeutics	Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics acrivon.com ↗
2023-09-19	Acrivon Therapeutics	Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics acrivon.com ↗
2023-05-09	Acrivon Therapeutics	Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer acrivon.com ↗
2022-06-22	Acrivon Therapeutics	Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368 acrivon.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	ACR-368	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06597565 ↗ 1 NCT05548296 ↗
Route	Intravenous	“ACR-368 105 mg/m2 IV every 2 weeks” NCT06597565 ↗